Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Healthcare Sector Analysis

UpdatedMay 02, 2026
DataAggregated Company Financials
Companies1401
  • 7D0.3%
  • 3M-5.1%
  • 1Y8.0%
  • YTD-5.5%

Last week, the Healthcare industry hasn't moved much but Eli Lilly is up 9.0% in that time. The past year has been better, since the industry has gained 8.0% in that time. Earnings are forecast to grow by 17% annually.

Sector Valuation and Performance

Has the U.S. Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 02 May 2026US$6.2tUS$3.3tUS$118.0b23.6x52.5x1.9x
Mon, 30 Mar 2026US$6.0tUS$3.3tUS$125.9b21.8x47.5x1.8x
Wed, 25 Feb 2026US$6.6tUS$3.3tUS$127.8b26.6x51.8x2x
Fri, 23 Jan 2026US$6.7tUS$3.2tUS$130.5b27.9x51x2.1x
Sun, 21 Dec 2025US$6.5tUS$3.2tUS$135.2b26.2x48x2x
Tue, 18 Nov 2025US$6.2tUS$3.2tUS$133.4b25.6x46.8x2x
Thu, 16 Oct 2025US$5.9tUS$3.1tUS$140.4b24.5x42.3x1.9x
Sat, 13 Sep 2025US$5.8tUS$3.1tUS$137.6b22.7x42.1x1.9x
Mon, 11 Aug 2025US$5.4tUS$3.1tUS$139.7b23.3x38.5x1.7x
Wed, 09 Jul 2025US$5.5tUS$3.0tUS$127.9b24.2x42.9x1.8x
Fri, 06 Jun 2025US$5.4tUS$3.0tUS$127.2b23.4x42.8x1.8x
Sun, 04 May 2025US$5.6tUS$2.7tUS$126.2b24.8x44.1x2x
Tue, 01 Apr 2025US$5.6tUS$2.6tUS$81.9b26.3x69x2.1x
Thu, 27 Feb 2025US$5.9tUS$2.6tUS$79.6b25.5x73.7x2.2x
Sat, 25 Jan 2025US$6.0tUS$2.9tUS$85.5b27.9x70.7x2.1x
Mon, 23 Dec 2024US$5.8tUS$2.9tUS$78.2b27.7x73.5x2x
Wed, 20 Nov 2024US$5.9tUS$2.9tUS$76.7b27.1x77.3x2x
Fri, 18 Oct 2024US$6.2tUS$2.8tUS$58.6b31.2x106.6x2.2x
Sun, 15 Sep 2024US$6.3tUS$2.8tUS$60.0b30.6x105.4x2.2x
Tue, 13 Aug 2024US$6.0tUS$2.8tUS$55.3b30.1x108.9x2.1x
Thu, 11 Jul 2024US$6.2tUS$2.8tUS$62.2b30x99x2.2x
Sat, 08 Jun 2024US$6.2tUS$2.8tUS$63.7b30x97.5x2.2x
Mon, 06 May 2024US$6.0tUS$2.8tUS$65.2b31.1x92.6x2.1x
Wed, 03 Apr 2024US$6.3tUS$2.8tUS$84.0b32.5x74.9x2.3x
Fri, 01 Mar 2024US$6.3tUS$2.8tUS$84.2b30.9x74.6x2.3x
Sun, 28 Jan 2024US$6.3tUS$2.8tUS$90.7b32x69.7x2.2x
Tue, 26 Dec 2023US$6.2tUS$2.8tUS$91.5b33.1x67.4x2.2x
Thu, 23 Nov 2023US$5.8tUS$2.8tUS$91.2b28x63.5x2.1x
Sat, 21 Oct 2023US$5.7tUS$2.8tUS$99.6b25.6x57.7x2.1x
Mon, 18 Sep 2023US$6.0tUS$2.8tUS$98.6b29.3x61x2.2x
Wed, 16 Aug 2023US$6.2tUS$2.8tUS$99.4b29x62.3x2.2x
Fri, 14 Jul 2023US$5.9tUS$2.7tUS$110.5b26.3x53.4x2.2x
Sun, 11 Jun 2023US$6.0tUS$2.7tUS$110.4b25.2x53.9x2.2x
Tue, 09 May 2023US$6.0tUS$2.7tUS$111.2b24.9x54.2x2.2x
Price to Earnings Ratio

54.2x


Total Market Cap: US$6.0tTotal Earnings: US$111.2bTotal Revenue: US$2.7tTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Healthcare Sector Price to Earnings3Y Average 65.5x202420252026
Current Industry PE
  • Investors are pessimistic on the American Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 52.5x which is lower than its 3-year average PE of 65.5x.
  • The industry is trading close to its 3-year average PS ratio of 2.1x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 2.0% per year over the last three years.
  • Revenues for these companies have grown 6.5% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare sector?

US Market0.80%
Healthcare0.29%
Healthcare Services3.46%
Pharma3.28%
Healthtech2.73%
Life Sciences-0.28%
Biotech-2.53%
Medical Equipment-4.27%
Industry PE
  • Investors are most optimistic about the Medical Equipment industry even though it's trading below its 3-year average PE ratio of 55.2x.
    • Analysts are expecting annual earnings growth of 15.6%, which is higher than its past year's earnings growth of 13.2% per year.
Forecasted Growth
  • Analysts are most optimistic on the Biotech industry, expecting annual earnings growth of 23% over the next 5 years.
  • However this is lower than its past earnings growth rate of 40% per year.
  • In contrast, the Pharma industry is expected to see its earnings grow by 14% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
LLY Eli LillyUS$963.339.0%
+US$71.0b		17.0%PE34.1x
ABBV AbbVieUS$206.604.0%
+US$14.0b		4.1%PE101.6x
UNH UnitedHealth GroupUS$368.783.9%
+US$12.6b		-7.8%PE27.8x
ELV Elevance HealthUS$372.688.1%
+US$6.1b		-9.1%PE15.4x
CNC CenteneUS$53.3427.5%
+US$5.8b		-11.3%PS0.1x

Latest News

TEVA
US$34.95
Teva Pharmaceutical Industries
7D
14.1%
1Y
115.9%
AMGN
US$329.82
Amgen
7D
-4.3%
1Y
17.3%
REGN
US$701.42
Regeneron Pharmaceuticals
7D
-6.7%
1Y
15.8%
SYK
US$294.73
Stryker
7D
-10.0%
1Y
-22.1%
LLY
US$963.33
Eli Lilly
7D
9.0%
1Y
17.0%
PFE
US$26.33
Pfizer
7D
-2.5%
1Y
8.8%

Pfizer: Why You Should Double Down Into Q1

May 01
HUM
US$233.63
Humana
7D
8.5%
1Y
-9.6%
ABBV
US$206.60
AbbVie
7D
4.0%
1Y
4.1%
UNH
US$368.78
UnitedHealth Group
7D
3.9%
1Y
-7.8%
ELV
US$372.68
Elevance Health
7D
8.1%
1Y
-9.1%

ELV: Regulatory And Margin Risks Will Pressure 2026 Earnings Visibility

The updated analyst price target for Elevance Health edges to $331 from $332, as analysts factor in slightly stronger revenue growth and profit margin assumptions, along with a modestly lower future P/E multiple, following a mix of recent upgrades, raised targets, and a few cautious revisions across the Street. Analyst Commentary Street research on Elevance Health has been mixed, with several firms lifting price targets while others trim expectations or shift to a more cautious stance.
BSX
US$56.50
Boston Scientific
7D
-9.0%
1Y
-46.2%
CNC
US$53.34
Centene
7D
27.5%
1Y
-11.3%

CNC: Policy And Exchange Uncertainty Will Pressure Margins And Constrain Upside

Analysts have trimmed the fair value estimate for Centene to $43.47 from $44.18, reflecting updated views on revenue growth, margin potential, and a lower expected future P/E multiple, even as several recent price target revisions highlight ongoing debate around the stock. Analyst Commentary Recent Street research paints a mixed picture for Centene, with several firms adjusting price targets and ratings as they reassess the company after Q4 results, updated guidance, and regulatory developments.
MDT
US$80.00
Medtronic
7D
-4.0%
1Y
-5.7%
ISRG
US$457.78
Intuitive Surgical
7D
-5.1%
1Y
-13.5%
CVS
US$82.09
CVS Health
7D
5.3%
1Y
21.7%

CVS: Medicare Advantage Turnaround And FTC Settlement Will Support Future Earnings

CVS Health's analyst price targets have edged higher by a few dollars, as analysts factor in slightly stronger revenue and margin assumptions, a modestly lower discount rate, and a somewhat lower future P/E multiple in light of recent research that highlights Medicare Advantage exposure, potential earnings stability in pharmacy, and reduced regulatory uncertainty tied to a possible FTC settlement. Analyst Commentary Recent research on CVS Health reflects a mix of cautious optimism and ongoing concern, with analysts adjusting price targets by only a few dollars in either direction as they reassess earnings quality, regulatory risks, and Medicare Advantage exposure.
SMMT
US$16.12
Summit Therapeutics
7D
-27.0%
1Y
-42.2%